The Phase II study of Everolimus for sporadic Angiomyolipomas (AMLs) was sponsored by Fox Chase Cancer Center and involved collaboration with Novartis Pharmaceuticals. The study aimed to evaluate the efficacy and tolerability of Everolimus, an already approved drug for other indications, in reducing tumor volume in patients with AMLs. The termination of the trial due to extreme toxicity raises concerns about the drug's safety profile in this specific indication, which could impact its commercial viability. The market for AML treatment is limited, as these tumors are non-cancerous; however, successful outcomes could position Everolimus as a treatment option for patients who are not candidates for surgical intervention. Competitive analysis indicates that alternative therapies may be limited, but the safety concerns could deter further investment or development in this area.